OUTSOURCED PHARMA CAPACITY UPDATE LARGE MOLECULE VIDEOS
Resilience Capacity Update July 2025: Large Molecule Drug Substance
Hear from Evan Pasenello, Head of Commercial Services, about how Resilience can support large molecule programs from early phase through clinical and commercial manufacturing.
Novartis Contract Manufacturing Capacity Update July 2025: Large Molecule Drug Substance
Review biologics CDMO solutions and capacity offered by Novartis Contract Manufacturing. We discuss our capabilities in mammalian cell culture manufacturing and microbial fermentation.
FUJIFILM Biotechnologies Capacity Update July 2025: Large Molecule Drug Substance
Review the strategic application of extensive expertise in microbial systems to meet the increasing demand for novel biologics. Cutting-edge capabilities ensure streamlined development and manufacturing processes.
Cytovance Biologics Capacity Update July 2025: Large Molecule Drug Substance
Thomas Kohl, Director of Business Development, shares the company’s microbial and mammalian capabilities and their available capacity. Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients alike.
Aragen Capacity Update July 2025: Large Molecule Drug Substance
Aragen’s newly built cutting-edge biologics manufacturing facility launches with GMP capabilities from 50L to 2000L—scaling to 5000L soon—with a DP filling line and ADC conjugation suite set to redefine bioproduction in India.
Northway Biotech Capacity Update April 2025: Large Molecule Development
Detra Glinatsis, Vice President of Business Development, presents the advanced capabilities, strategic growth, and expanding capacity of Northway Biotech, a global biologics CDMO.
Abzena Capacity Update April 2025: Large Molecule Development
See first-hand how AbZelectPRO™, an evolved approach to cell line development, can simplify selection, enhance stability, and de-risk your program for faster regulatory approval.
Curia Capacity Update April 2025: Large Molecule Development
Site head Bill Hermans showcases our facility's specialized capabilities in Hopkinton, Massachusetts, and shares how our team serves as a true scientific partner to clients.
Cytovance Biologics Capacity Update April 2025: Large Molecule Development
Speed up your program with end-to-end microbial and mammalian biologics development and manufacturing expertise — spanning everything from biosimilars to vaccines.
Novartis Capacity Update April 2025: Large Molecule Development
Experience a global network of expertise and proven manufacturing capabilities that can help accelerate your clinical and commercial drug substance programs.
Samsung Biologics Capacity Update April 2025: Large Molecule Development
Leveraging advanced technology, expertise, and flexible capacity, clients can reduce development time and costs while ensuring a smooth transition from clinical to commercial manufacturing.
Boehringer Ingelheim Capacity Update April 2025: Large Molecule Development
Explore how world-class contract manufacturing expertise and global capabilities can help accelerate your biologic from development to commercial success.
Leveraging Advanced Technology And Proven Expertise
By leveraging our proprietary non-viral gene insertion technology, GPEx® Lightning ensures rapid development timelines and high-yield production, making it an ideal solution for complex biologics.
FUJIFILM Diosynth Biotechnologies Capacity Update April 2025: Large Molecule Development
Associate Director kojoX and Technology Development, Rasmus Petersen, presents a high-level overview of FDB’s capabilities, its global facilities network, and capacity updates for BIOLOGICS.
Northway Biotech Capacity Update January 2025: Large Molecule Development
Over the past 20 years, we have completed more than 175 successful projects around the globe, showcasing our commitment to quality and customer satisfaction.
Mabion Capacity Update January 2025: Large Molecule Development
Go on a virtual tour of our GMP-certified facility, where we uphold our expanded capabilities for large molecule development to the highest standards for clinical and commercial manufacturing.
KBI Biopharma Capacity Update January 2025: Large Molecule Development
Follow along as Derek Ryan, Sr. Director of Analytical Development, showcases our high-throughput technology and digital tools for process understanding and optimizing decision-making.
Cytovance Biologics Capacity Update January 2025: Large Molecule Development
Join Rose Rhomberg, Senior Business Development Director, as she showcases Cytovance’s microbial and mammalian capabilities, along with our available manufacturing capacity.
Catalent Capacity Update January 2025: Large Molecule Development
Learn how our expertise and advanced capabilities provide customized analytical solutions that ensure quality, precision, and regulatory compliance for your biotherapeutics.
Northway Biotech Capacity Update October 2024: Large Molecule Drug Substance
We have the capabilities, competitive advantages, and capacity to onboard new projects across two facilities: Waltham, MA, operational since 2020, and Vilnius, Lithuania, established in 2004.
Cytovance Biologics Capacity Update October 2024: Large Molecule Drug Substance
Senior Business Development Director Rose Rhomberg presents an in-depth look at Cytovance’s capabilities and highlights the available capacity designed to accelerate your goals.
Novartis Contract Manufacturing Capacity Update October 2024: Large Molecule Drug Substance
Gain valuable insights into our mammalian development services, manufacturing solutions, upcoming capacity availability, as well as updates on expansion timelines for external clients.
Pfizer CentreOne Capacity Update October 2024: Large Molecule Drug Substance
See how our specialized manufacturing site in Sanford, NC — backed by over 35 years of expertise in mAb production — can expedite the delivery of your groundbreaking therapies to patients.
Resilience Capacity Update October 2024: Large Molecule Drug Substance
Business Head of Biologics and Vaccines Evan Pasenello shares how Resilience’s innovative platforms and specialized expertise can effectively support your development and manufacturing programs.
Boehringer Ingelheim BioXcellence™ Capacity Update October 2024: Large Molecule Drug Substance
Explore our global production network, advanced aseptic filling, in-house analytics, and the expertise that has driven 47 biopharmaceuticals to market success.
FUJIFILM Diosynth Biotechnologies Capacity Update October 2024: Large Molecule Drug Substance
Rasmus Pedersen, Ph.D., outlines strategies to expand large-molecule production capacity to meet the global medicine demand, noting the current gap that leaves 2 billion people without access.
Samsung Biologics Capacity Update October 2024: Large Molecule Drug Substance
We're poised to be your next growth engine with our commitment to quality, speed, and agility, as we expand our facilities and invest in innovative modalities to meet your large molecule needs.
Cytovance Capacity Update July 2024: Large Molecule Development
Centrally located in the United States, with a decades-long history in biologics development and manufacturing, Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients alike.
Agenda & Presenter Details
Visit our registration pages to see the current agenda and our list of presenting sponsors.
How can we help?
Are you a supplier looking to present at our next event?